The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
Figure 1.The outcomes of survival between hyperthermia group and non-hyperthermia group. (A) 1-year OS rates between two groups (P<0.05). (B) 1-year PFSfirst rates between two groups (P<0.01).